Pre-Submission Review for Cell Biology Journals: What Nature Cell Biology and Molecular Cell Reviewers Expect

Reviewers at Cell, Nature Cell Biology, and Molecular Cell go straight to the figures in the initial screen. In the first read they are testing:

• Whether representative images are actually representative: the panel is a typical field from multiple independent experiments, not the single best field cherry-picked from one run.

• Whether quantification carries the claim: every quantitative statement is backed by counts from at least three independent biological replicates, with the number of cells per condition stated, not technical replicates.

• Whether the statistics fit the data: the test matches the data type, error bars are defined, and n values are explicit rather than implied.

• Whether imaging is documented: scale bars on every micrograph, microscope/objective/channel/exposure recorded, and any processing applied equally across all conditions with raw images available.

• Whether the mechanism is demonstrated, not asserted: gain-of-function, loss-of-function, and rescue are present, so the causal bridge is shown rather than inferred from a localization or correlation.

• Whether validation spans more than one system: the finding holds beyond a single cell line or construct (primary cells, endogenous levels, in vivo where feasible, or an orthogonal method).

• Whether the novelty claim survives the last 18 to 24 months of literature in the target journals and the fast-moving subfield around it.

If two or more of these are unresolved, the paper is a desk-rejection or major-revision risk regardless of how attractive the imaging is.

Across cell biology manuscripts targeting Cell, Nature Cell Biology, and Molecular Cell, the same failure patterns recur. Each names a manuscript component so you can test your own draft against it.

Representative image outruns the quantification: The main figures show a striking phenotype, but the quantification rests on a handful of cells from a single experiment, or no quantification is shown at all. Reviewers treat a beautiful panel without numbers underneath as a credibility problem before figure two.

Localization written as mechanism: The manuscript shows that a protein localizes to an organelle or interacts with a partner, then writes the abstract as if the causal mechanism is established. Without domain mapping, a phosphosite, or a disruption-rescue chain, the strongest sentence overruns the evidence.

Single-system evidence framed as general biology: The result is established only in HeLa or HEK293, with no primary-cell, endogenous-level, or in vivo confirmation, yet the discussion generalizes to "cells" broadly. In areas where model choice matters, this is the most common reviewer objection.

Genetic perturbation without rescue or orthogonal control: A knockout or single-siRNA phenotype carries a core claim with no re-expression rescue, no second independent siRNA/CRISPR guide, and no protein-level confirmation of the knockdown. The methods often omit the replicate count and the statistics for the perturbation, and the supplementary data does not include the source blots; for a flagship paper this is a predictable revision request.

Biochemical interaction shown by one method, with tags only: A central interaction rests on a single co-IP using overexpressed tagged constructs, with no endogenous demonstration and no orthogonal method (proximity ligation, FRET, or pulldown). Reviewers discount single-method, overexpression-only interactions.

Novelty overlap the authors did not pre-empt: A paper published 8 to 12 months earlier established a similar mechanism in a related system, and the manuscript does not explain why this finding is distinct and additive. This is the single most common avoidable desk-rejection trigger in a fast-moving field.

Reporting-summary friction: Nature Portfolio pages require authors to make data, code, materials, and protocols available enough for others to replicate and build on the claims. We see strong cell biology drafts weaken when the reporting summary, source images, antibody validation, statistics, and availability statements are assembled late instead of being treated as part of the main evidence package.

These patterns are why a figure-rigor and mechanism check before submission is worth more than a faster light pass for this tier.

Public author guidance and reporting standards tell you what these journals enforce even before peer review. Use them as a checklist.

• Cell and Molecular Cell follow Cell Press author guidance, including STAR Methods and a key-resources table that forces antibody, cell-line, construct, and reagent transparency.

• Nature Cell Biology requires the Nature Portfolio reporting summary: statistics, randomization, blinding, replicate numbers, and antibody-validation disclosures at submission.

• Image-integrity policies across these journals require unprocessed source images and prohibit selective adjustment; gel and blot source data are increasingly mandatory.

• Cross-field reporting frameworks apply: ARRIVE for animal studies, data-availability statements for sequencing and imaging data (GEO, BioImage Archive), and cell-line authentication and mycoplasma testing disclosure.

• Nature Portfolio image-integrity guidance asks authors to document acquisition tools, processing software, settings, and manipulations. For a cell biology paper, that turns microscopy methods and source-image files into editorial evidence, not afterthoughts.

Method note: this page relies on public author guidance and our own anonymized pre-submission review patterns. It is not based on private editorial or reviewer access, and journals update author instructions, so verify current requirements against each journal's live author pages before submission.

For a productive cell biology pre-submission review, send the full package, not just the manuscript:

• The full manuscript with figures and figure legends

• The target journal and any backup journals you are considering

• Supplementary figures, especially the source images and gating or quantification data

• Underlying data and any code used for image analysis or sequencing

• The reporting checklist or STAR Methods key-resources table if drafted

• Any prior reviewer comments from an earlier submission

A review that is worth paying for ends with a clear instruction to submit, revise, retarget, or diagnose, plus the evidence for that call. Specifically it should deliver:

• A verdict on whether the manuscript clears the bar for the named target journal or a step-down

• The two or three reviewer objections most likely to appear, in reviewer language

• Component-level fixes: which figure, which quantification, which control, which abstract sentence

• A novelty assessment against recent literature in the target journals

• A multi-system-validation call for single-system or overexpression-only results

• A journal-fit edit on title, abstract, and the first two introduction paragraphs

High-value feedback is specific and testable: it references exact claims, figures, and likely reviewer comments, and each point changes the acceptance odds if fixed. Low-value feedback stays at writing-style level. For a fast first pass on a cell biology manuscript, run a manuscript readiness check.

Use this page when the question is whether a cell biology manuscript is ready for a specific top journal and what a review of it should cover.

Use the Nature Cell Biology review-time page when the question is how long a decision takes, use the Nature Cell Biology JIF page when the question is the journal's metrics, and use how pre-submission review works when the question is the general service across all fields.

Keeping each job on one page is what lets each rank for its own intent.

Target Cell if:

• The mechanism is complete and the finding reshapes how a field thinks

• You have multi-system validation (cell lines, primary cells, in vivo)

• The story builds from observation through mechanism to function with breadth

• Every major claim is carried by quantified, orthogonal evidence

Target Nature Cell Biology or Molecular Cell if:

• The conceptual or molecular-mechanism advance is exceptional but more focused

• Significance is primarily within cell biology, executed to flagship standards

• You have rescue, endogenous, and second-method validation throughout

Target a step-down (JCB, Current Biology, or a specialist journal) if:

• The mechanism is solid but does not reach top-tier significance

• The work is focused on one system without broader implications

• You need a faster decision or a less competitive venue

Ready to submit if

• the main figures remain convincing after you ignore the prose and read only the legends, quantification, and controls

• the mechanistic claim is narrower than the strongest evidence, not broader

• at least one independent validation context makes the central result look durable

Pause first if

• the representative images look stronger than the quantified data

• rescue, endogenous confirmation, or second-system validation is still missing from a core mechanistic claim

• the target journal expects more depth than the current figure-and-validation package can support

For a manuscript-specific signal before you submit, run a cell biology submission readiness check. Or see example reports before you finalize.

• Cell biology teams choosing between Cell, Nature Cell Biology, Molecular Cell, and a step-down before first submission

• Authors who need an external check on figure rigor, mechanistic completeness, and multi-system validation

• Labs trying to identify likely reviewer objections before upload